Vardenafil Tablets

rufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. selpercatinibselpercatinib increases toxicity of vardenafil by QTc interval.

LinkOut - more resources

rilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ritonavirritonavir will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Adjust dosage of CYP3A4 substrates, if clinically indicated. rucaparib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rufinamiderufinamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. selpercatinib increases toxicity of vardenafil by QTc interval. Coadministration of sepiapterin with drugs affecting nitric oxide-mediated relaxation may cause additive vasodilation and further reduce blood pressure. sertralinesertraline and vardenafil both increase QTc interval. sertraline and vardenafil both increase QTc interval. Consider predose and post-colonoscopy ECGs in patients at increased risk of serious super tadapox 100mg cardiac arrhythmias. sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of vardenafil by QTc interval. sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of vardenafil by QTc interval. solifenacinsolifenacin and vardenafil both increase QTc interval.

solifenacin and vardenafil both increase QTc interval. sorafenibsorafenib and vardenafil both increase QTc interval. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects.

Initial Information

olanzapine and vardenafil both increase QTc interval. olodaterol inhaledvardenafil and olodaterol inhaled both increase QTc interval. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias vardenafil and olodaterol inhaled both increase QTc interval. osilodrostat and vardenafil both increase QTc interval. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.

Medical Professionals

osimertinib and vardenafil both increase QTc interval. ozanimodozanimod and vardenafil both increase QTc interval. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties. ozanimod and vardenafil both increase QTc interval. vardenafil and pasireotide both increase QTc interval.

Mechanism of Action

pentobarbitalpentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. pentobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbitalphenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenobarbital will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. phenytoinphenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sunitinibsunitinib and vardenafil both increase QTc interval. sunitinib and vardenafil both increase QTc interval. suzetriginesuzetrigine decreases levels of medicine for erectile dysfunction vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients for loss of therapeutic effect of sensitive CYP3A substrates with narrow therapeutic indexes when coadministered with suzetrigine.

Consider modifying dose of sensitive substrate according to prescribing recommendations.

• Vardenafil contact info for adverse events reporting.
• It is one of several PDE5 inhibitors on the market.
• The medication requires sexual arousal to be effective.
• Take Vardenafil approximately 30 minutes before intimacy.
• Do not share your medication with others.
• Ensure proper hydration to help with absorption.
• The half-life of Vardenafil is around 4-5 hours.
• Do not use Vardenafil if you have had recent stroke or MI.
• Inform your doctor about all health conditions before use.
• Use Vardenafil responsibly to prevent dependency.
• Follow prescribed dosage for optimal results.

suzetrigine decreases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Concomitant use may increase the risk of QTc interval prolongation. If concomitant use is unavoidable, adjust the frequency of ECG and electrolyte monitoring. tecovirimattecovirimat will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered. tecovirimat will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

tetracyclinetetracycline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors tetracycline will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors tobramycin inhaledtobramycin inhaled and vardenafil both increase nephrotoxicity and/or ototoxicity. Avoid concurrent or sequential use to decrease risk for ototoxicity tobramycin inhaled and vardenafil both increase nephrotoxicity and/or ototoxicity. Avoid concurrent or sequential use to decrease risk for ototoxicity topiramatetopiramate will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

4. Clinical Efficacy and Comparative Advantages

phenytoin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. posaconazoleposaconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors posaconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors prednisoneprednisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. prednisone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Subscribe to MedicineNet's Men's Health Newsletter

primaquineprimaquine and vardenafil both increase QTc interval. primaquine and vardenafil both increase QTc interval. primidoneprimidone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. primidone will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Either increases toxicity of the other by QTc interval.

Individual Physiology:

Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known super p force 160mg to cause electrolyte imbalance or prolong QT. quininevardenafil and quinine both increase QTc interval. vardenafil and quinine both increase QTc interval. Monitor patients more frequently with ECG if coadministered with QT prolonging drugs. topiramate will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. valbenazinevalbenazine and vardenafil both increase QTc interval. valbenazine and vardenafil both increase QTc interval. verapamilverapamil will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors verapamil will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors Either increases effects of the other by QTc interval. voriconazolevoriconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors voriconazole will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors vorinostatvorinostat and vardenafil both increase QTc interval. vorinostat and vardenafil both increase QTc interval. zafirlukastzafirlukast will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil is contraindicated for women and children.
• It can be used by men with diabetes-related erectile issues.
• It's effective for men with prostate-related erectile problems.
• Always measure dosage carefully to avoid adverse effects.
• The medication is absorbed in the gastrointestinal tract.
• Vardenafil does not protect against sexually transmitted infections.
• Use caution if combining with other medications affecting circulation.
• Some people may experience indigestion or stomach pain.
• It is important to report any severe side effects immediately.
• The drug's efficacy may be affected by certain medical conditions.
• Always complete the full course prescribed by your doctor.

zafirlukast will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. acetazolamideacetazolamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

6. Patient Counseling and Practical Tips

relacorilantrelacorilant increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce vardenafil dose if coadministered with a strong CYP3A4 inhibitor. relacorilant increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ECG monitoring recommended if concomitant use can?t be avoided and withhold therapy if QTc interval is >480 msec; restart therapy after QTc interval returns to <480 msec revumenib and vardenafil both increase QTc interval. ECG monitoring recommended if concomitant use can?t be avoided and withhold therapy if QTc interval is >480 msec; restart therapy after QTc interval returns to <480 msec ribociclibribociclib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

What is vardenafil, and what is it used for?

Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors ribociclib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors rifapentinerifapentine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifapentine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rilzabrutinibrilzabrutinib increases levels of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Reduce vardenafil dose if coadministered with moderate CYP3A inhibitors.